Efficacy, safety and influencing factors of intra‑calf muscular injection of bone marrow mononuclear cells in the treatment of type 2 diabetes mellitus‑induced lower extremity vascular disease

Mostly low- and very low-quality evidence suggests no clear differences between different stem cell sources and different treatment regimens of autologous cell implantation for outcomes such as all-cause mortality, amputation rate, ulcer healing, and rest pain for 'no-option' CLI patients. Pooled analyses did not show a clear difference in clinical outcomes whether cells were administered via IM or IA routes. High-quality evidence is lacking; therefore the efficacy and long-term safety of autologous cells derived from different sources, prepared using different protocols, administered at different doses, and delivered via different routes for the treatment of 'no-option' CLI patients, remain to be confirmed.Future RCTs with larger numbers of participants are needed to determine the efficacy of cell-based therapy for CLI patients, along with the optimal cell source, phenotype, dose, and route of implantation. Longer follow-up is needed to confirm the durability of angiogenic potential and the long-term safety of cell-based therapy.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Efficacy, safety and influencing factors of intra‑calf muscular injection of bone marrow mononuclear cells in the treatment of type 2 diabetes mellitus‑induced lower extremity vascular disease

Cited by 2 publications

References 32 publications

Local intramuscular transplantation of autologous bone marrow mononuclear cells for critical lower limb ischaemia

Local intramuscular transplantation of autologous bone marrow mononuclear cells for critical lower limb ischaemia

Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients

Contact Info

Product

Resources

About